EPIX NASDAQ
ESSA Pharma Inc.
1W: -7.5%
1M: -1.9%
3M: -5.0%
1Y: -73.6%
3Y: -9.2%
5Y: -75.2%
$0.20
Last traded 2025-10-09 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$9.5M
52W Range0.18-6.45
Volume5,945,141
Avg Volume6,752,718
Beta1.53
Dividend$1.69
Analyst Ratings
Company Info
CEODavid Ross Parkinson
Employees35
SectorHealthcare
IndustryBiotechnology
IPO Date2015-03-13
Websiteessapharma.com
999 West Broadway
Vancouver, BC V5Z 1K5
CA
Vancouver, BC V5Z 1K5
CA
17783310962
About ESSA Pharma Inc.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Parkinson David Ross | D-Return | 65,675 | $0.12 | 2025-10-09 |
| Wood David S. | D-Return | 33,343 | $0.12 | 2025-10-09 |
| BERGER FRANKLIN M | D-Return | 784,404 | $0.12 | 2025-10-09 |
| Glickman Richard M | D-Return | 43,240 | $0.12 | 2025-10-09 |
| Requadt Scott | D-Return | 30,002 | $0.12 | 2025-10-09 |